Pharsight

Azstarys is owned by Commave Therap.

Azstarys contains Dexmethylphenidate Hydrochloride; Serdexmethylphenidate Chloride.

Azstarys has a total of 6 drug patents out of which 0 drug patents have expired.

Azstarys was authorised for market use on 07 May, 2021.

Azstarys is available in capsule;oral dosage forms.

Azstarys can be used as treatment of attention-deficit hyperactivity disorder (adhd) with serdexmethylphenidate and dexmethylphenidate.

Drug patent challenges can be filed against Azstarys from 2025-05-07.

The generics of Azstarys are possible to be released after 09 December, 2037.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10584112	COMMAVE THERAP	Methylphenidate-prodrugs, processes of making and using the same	Dec, 2037 (14 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079928	COMMAVE THERAP	Methylphenidate-oxoacid conjugates, processes of making and using the same	Jul, 2032 (9 years from now)
US10858341	COMMAVE THERAP	Compositions comprising methylphenidate-prodrugs, processes of making and using the same	Dec, 2037 (14 years from now)
US10954213	COMMAVE THERAP	Compositions comprising methylphenidate-prodrugs, processes of making and using the same	Dec, 2037 (14 years from now)
US10584113	COMMAVE THERAP	Methylphenidate-prodrugs, processes of making and using the same	Dec, 2037 (14 years from now)
US10759778	COMMAVE THERAP	Methylphenidate-prodrugs, processes of making and using the same	Dec, 2037 (14 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 7, 2026

NCE-1 date: 2025-05-07

Market Authorisation Date: 07 May, 2021

Treatment: Treatment of attention-deficit hyperactivity disorder (adhd) with serdexmethylphenidate and dexmethylphenidate

Dosage: CAPSULE;ORAL